Emzor Pharmaceuticals to Establish Anti-Malarial API Facility in Ogun State, Nigeria
Emzor Pharmaceuticals, a leading pharmaceutical company in Nigeria, has announced plans to invest $23 million (over N25 billion) in the establishment of an Active Pharmaceutical Ingredients (API) facility in Sagamu, Ogun State. This groundbreaking initiative aims to combat the pervasive threat of malaria in Nigeria and Sub-Saharan Africa.
Once operational, the API facility will be the first of its kind in Nigeria and Africa, dedicated to the production of anti-malarial APIs. With a projected annual output of 400 metric tonnes of quality APIs, the facility is poised to significantly accelerate the fight against malaria in the region.
Background:
The decision to establish the API facility follows a significant announcement made last October during the EU-Nigeria Strategic Dialogue. At that time, the European Investment Bank (EIB) pledged €14 million in funding to Emzor Pharmaceutical Industries Limited to support efforts to combat malaria in Africa. The funding was earmarked for the construction of Nigeria’s first antimalarial API manufacturing plant.
This strategic project aims to reduce Nigeria’s heavy reliance on imported APIs, which currently accounts for over 90% of the country’s API needs. By producing high-quality and affordable anti-malarial drugs domestically, the API facility will contribute to strengthening Nigeria’s healthcare sector and bolstering the country’s self-sufficiency in pharmaceutical production.
Expected Impact:
Upon completion, the API facility is expected to create over 500 jobs, providing employment opportunities and economic empowerment to local communities in Ogun State. Furthermore, the facility will pave the way for future expansion into additional therapeutic areas, further enhancing Nigeria’s pharmaceutical capabilities.
Partnerships and Collaboration:
Emzor Pharmaceuticals has forged a strategic partnership with Mangalam Drugs and Organics Limited, an Indian pharmaceutical company, for technology transfer, training, testing, and initial production at the API facility site. This collaboration underscores Emzor’s commitment to leveraging global expertise and best practices to advance healthcare innovation in Nigeria and beyond.
The establishment of the anti-malarial API facility represents a significant milestone in Nigeria’s efforts to combat malaria and improve access to essential medicines. Emzor Pharmaceuticals’ investment underscores its dedication to addressing pressing healthcare challenges and driving positive change in the region.
As construction commences on the API facility, stakeholders anticipate a transformative impact on healthcare delivery and malaria control efforts in Nigeria and across Sub-Saharan Africa.
Date: [Insert Date]
Emzor Pharmaceuticals, a leading pharmaceutical company in Nigeria, has announced plans to invest $23 million (over N25 billion) in the establishment of an Active Pharmaceutical Ingredients (API) facility in Sagamu, Ogun State. This groundbreaking initiative aims to combat the pervasive threat of malaria in Nigeria and Sub-Saharan Africa.
Once operational, the API facility will be the first of its kind in Nigeria and Africa, dedicated to the production of anti-malarial APIs. With a projected annual output of 400 metric tonnes of quality APIs, the facility is poised to significantly accelerate the fight against malaria in the region.
Background:
The decision to establish the API facility follows a significant announcement made last October during the EU-Nigeria Strategic Dialogue. At that time, the European Investment Bank (EIB) pledged €14 million in funding to Emzor Pharmaceutical Industries Limited to support efforts to combat malaria in Africa. The funding was earmarked for the construction of Nigeria’s first antimalarial API manufacturing plant.
This strategic project aims to reduce Nigeria’s heavy reliance on imported APIs, which currently accounts for over 90% of the country’s API needs. By producing high-quality and affordable anti-malarial drugs domestically, the API facility will contribute to strengthening Nigeria’s healthcare sector and bolstering the country’s self-sufficiency in pharmaceutical production.
Expected Impact:
Upon completion, the API facility is expected to create over 500 jobs, providing employment opportunities and economic empowerment to local communities in Ogun State. Furthermore, the facility will pave the way for future expansion into additional therapeutic areas, further enhancing Nigeria’s pharmaceutical capabilities.
Partnerships and Collaboration:
Emzor Pharmaceuticals has forged a strategic partnership with Mangalam Drugs and Organics Limited, an Indian pharmaceutical company, for technology transfer, training, testing, and initial production at the API facility site. This collaboration underscores Emzor’s commitment to leveraging global expertise and best practices to advance healthcare innovation in Nigeria and beyond.
The establishment of the anti-malarial API facility represents a significant milestone in Nigeria’s efforts to combat malaria and improve access to essential medicines. Emzor Pharmaceuticals’ investment underscores its dedication to addressing pressing healthcare challenges and driving positive change in the region.
As construction commences on the API facility, stakeholders anticipate a transformative impact on healthcare delivery and malaria control efforts in Nigeria and across Sub-Saharan Africa.
